Zacks Investment Research upgraded shares of CYBIN INC. (CYBN.NE) (OTCMKTS:CYBN) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $2.25 target price on the stock.
According to Zacks, “Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada. “